Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAE609 Single Dose in Uncomplicated Malaria
NCT01860989Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cipargamin in Plasmodium falciparum malaria, sponsored by Novartis. Started Jul 2013; status: completed.
02
Drugs
cipargamin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01860989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860989.